Veraxa Biotech (VRXA) vs Zentalis Pharmaceuticals (ZNTL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Zentalis Pharmaceuticals (ZNTL) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 1.5% versus a loss of 90.1%. Veraxa Biotech is the larger company by market cap ($147.1 million vs $133.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VRXA | ZNTL |
|---|---|---|
| Share price | $1.04 | $1.36 |
| Market cap | $147.06M | $133.64M |
| 1-day change | +0.97% | 0.00% |
| YTD return | -90.25% | +0.74% |
| 1-year return | -90.10% | +1.49% |
| 5-year return | — | -98.21% |
| EPS (TTM) | $-0.57 | $-1.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $-137.06M |
| 52-week high | $27.36 | $6.95 |
| 52-week low | $0.90 | $1.30 |
| Distance from 52-week high | -96.20% | -80.43% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +447.06% |
| Average volume | 267.82K | 1.26M |
| Shares outstanding | 141.41M | 98.27M |
| Employees | — | 106 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ZNTL has outperformed VRXA by 91.6 percentage points over the past year.
About Veraxa Biotech
VRXA stock →Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
About Zentalis Pharmaceuticals
ZNTL stock →Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
VRXA vs ZNTL FAQ
Which is bigger, Veraxa Biotech or Zentalis Pharmaceuticals?
Veraxa Biotech (VRXA) is larger, with a market capitalization of $147.06M compared with $133.64M for Zentalis Pharmaceuticals (ZNTL).
Which stock has performed better over the past year, VRXA or ZNTL?
ZNTL returned +1.49% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Veraxa Biotech and Zentalis Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.